Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Nov 13;10(11):e0142970.
doi: 10.1371/journal.pone.0142970. eCollection 2015.

Detection and Characterization of Metastatic Cancer Cells in the Mesogastrium of Gastric Cancer Patients

Daxing Xie  1   2 , Liang Liu  1   2 , Hasan Osaiweran  1   2 , Chaoran Yu  1   2 , Fang Sheng  1   2 , Chun Gao  1   2 , Junbo Hu  1   2 , Jianping Gong  1   2
Affiliations

Detection and Characterization of Metastatic Cancer Cells in the Mesogastrium of Gastric Cancer Patients

Daxing Xie et al. PLoS One. .

Erratum in

Abstract

Gastric cancer is the second leading cause of cancer death worldwide. Here, we propose a novel type of tumor metastasis designated as Metastasis V in gastric cancer. Metastasis V is defined as the appearance of cancer cells in the mesogastrium with perigastric adipose tissue. To detect its incidence and characterize its clinic pathological features, large cross sectional tissue analysis of mesogastrium from 74 patients were used. Metastasis V was detected in 1 of 40 (2.5%) patients with early gastric cancer, 8 of 34 (24%) patients with advanced gastric cancer. The mean distance of Metastasis V from gastric wall was approximately 2.6 cm. Metastasis V was closely associated with tumor invasion depth, along with a number of positive lymph node metastasis. The prognosis of patients with Metastasis V was significantly (P<0.05) worse than those with tumor cell-free mesogastrium. These findings indicate that by using whole-sectional analysis, Metastasis V can be detected in the mesogastrium of gastric cancer patients, and also suggests that it may be a risk factor for patient survival after radical surgery.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Detection of Metastasis V in gastric cancer patients.
(A) Large cross sectional tissue samples analysis of mesogastrium from surgically resected specimens. mLGEV, mRGEV, mLGV and mRGV were analyzed. (B) Continuous sections at 1-cm-width intervals of mesogastrium specimens. (C) Isolated cancer cells were detected in the mesogastrium of resected gastric cancer specimens by both HE staining (left) and immunohistochemistry with CK AE1/AE3 antibody (right). (D) Distance of Metastasis V from the gastric walls.
Fig 2
Fig 2. Schema of locational relationship between primary tumor and Metastasis V in nine patients with Metastasis V.
Fig 3
Fig 3. The overall survival of patients with or without Metastasis V.
(A) The Kaplan–Meier overall survival curves showed the prognosis of Metastasis V-positive patients was significantly (P = 0.006) worse than Metastasis V-negative patients. (B-C) Metastasis V-positive patients had a significantly poorer prognosis than Metastasis V-negative patients in the T3 subgroup (P = 0.004; B) or in clinical stage III (P = 0.0005; C).
Fig 4
Fig 4. E-cadherin and DAB2IP expression in normal gastric mucosa, primary gastric tumors and Metastasis V within the mesogastrium.
(A) Representative IHC staining for DAB2IP and E-cadherin from the same patient. (B) The relative quantitative analysis of E-cadherin and DAB2IP expression. One asterisk indicated statistical significance in normal mucosa vs. primary tumors (*, P < 0.01). Two asterisks indicated statistical significance in primary tumors vs. mesogastrium (**, P<0.01).
See this image and copyright information in PMC

References

    1. Menges M, Hoehler T. Current strategies in systemic treatment of gastric cancer and cancer of the gastroesophageal junction. J Cancer Res Clin Oncol. 2009, 135: 29–38. 10.1007/s00432-008-0425-z - DOI - PMC - PubMed
    1. Dickson JL, Cunningham D. Systemic treatment of gastric cancer. Eur J Gastroenterol Hepatol. 2004, 16: 255–263. - PubMed
    1. Otsuji E, Kobayashi S, Okamoto K, Hagiwara A, Yamagishi H. Is timing of death from tumor recurrence predictable after curative resection for gastric cancer? World J Surg. 2001, 25: 1373–1376. - PubMed
    1. Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery—the clue to pelvic recurrence? Br J Surg. 1982, 69: 613–616. - PubMed
    1. Hohenberger W, Weber K, Matzel K, Papadopoulos T, Merkel S. Standardized surgery for colonic cancer: complete mesocolic excision and central ligation—technical notes and outcome. Colorectal Dis. 2009, 11: 354–364. 10.1111/j.1463-1318.2008.01735.x - DOI - PubMed

Publication types

MeSH terms